Sun Pharma Advanced Research Company reports standalone net loss of Rs 99.54 crore in the March 2020 quarter
Sun Pharma Advanced Research Company reports standalone net profit of Rs 56.69 crore in the June 2020 quarter
Sun Pharma Advanced Research Company announced the grant of an exclusive license to Tripoint Therapeutics LLC, USA (Tripoint) to commercialize Elepsia™ XR 1000 mg and Elepsia™ XR 1500 mg tablets in the USA.
Under terms of the license agreement, SPARC will be eligible to receive tiered royalties ranging from 15% to 50% on net sales.
Tripoint will be responsible for all US regulatory submissions and payment of annual PDUFA fees for Elepsia™ XR 1000 mg and Elepsia™ XR 1500 mg.
The initial term of the agreement shall be 5 years and may be further extended as per mutual agreement between the parties.
Powered by Capital Market - Live News
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)